The Firm is representing Acelity, a portfolio company of Apax Partners, CPP and PSP, in connection with its agreement to sell its LifeCell Business Unit to Allergan (NYSE: AGN) for $2.9 billion in cash. The transaction is expected to close in the first half of 2017, subject to the satisfaction of customary closing conditions.
LifeCell is recognized for applications in plastic and reconstructive surgeries and abdominal wall procedures. The LifeCell portfolio encompasses regenerative and reconstructive acellular tissue matrices for repair of soft tissue defects, as well as autologous fat grafting solutions. Leading products include ALLODERM™ Regenerative Tissue Matrix, a human allograft tissue matrix which allows for a strong, intact repair in breast reconstruction post-mastectomy procedures and other surgical applications, by providing soft tissue reinforcement; and STRATTICE™ Reconstructive Tissue, a porcine based tissue matrix for reinforcement of soft tissue in challenging hernia repair procedures.
The Simpson Thacher Team includes Ryerson Symons, Matt Rogers, Erika Tang and Sam Egendorf (M&A); Ken Wallach, Sunny Cheong and Benjamin Heriaud (Capital Markets); Brian Steinhardt (Credit); Brian Robbins, Joo Hyun Lee and Monisha Bhayana (Executive Compensation and Employee Benefits); Gary Mandel, Sophie Staples and Deborah Plum (Tax); Sara Razi, Ellen Frye, Jonathan Mincer and Lindsey Bohl (Antitrust); Lori Lesser, Linda Nyberg and Marissa Lambert (Intellectual Property); Steve DeLott (Insurance); and Mike Isby and Tim Mulvihill (Environmental).